Informed Prostate Cancer Patient Support

PrLZ regulates EMT and invasion in prostate cancer via the TGF‐β1/p‐smad2/miR‐200 family/ZEB1 axis - Xie - The Prostate - Wiley Online Library Hongjun Xie PhD ,  Jiaqi Chen PhD ,  Zhenkun Ma PhD ,  Yang Gao PhD ,  Jin Zeng PhD ,  Yule Chen PhD ,  Zhao Yang PhD ,  Shan Xu PhD First published: 25 December 2023 https://doi.org/10.1002/pros.24647 Abstract Background Prostate leucine zipper (PrLZ) is a prostate-specific protein, and our previous study demonstrated that PrLZ enhances the malignant progression of prostate cancer (Pca). However, the roles of PrLZ in epithelial to mesenchymal transition (EMT) remain unknown. Methods Quantitative real-time PCR (qRT-PCR), immunohistochemical (IHC) ...

Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials - ScienceDirect :  sciencedirect.com  , , , , , , , , , , , , , , , , , , https://doi.org/10.1016/j.ijrobp.2023.12.022 Abstract Purpose A suboptimal prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) among men who go on to receive definitive radiotherapy for prostate cancer might suggest the existence of castration-resistant disease or altered androgen receptor (AR) signaling. This in turn may portend worse long-term clinical outcomes, especially in men with high-risk disease. We set out to evaluate the prognostic impact of poor PSA response to neoadjuvant ADT in men with high-risk prostate cancer. Methods and Materials This was a post hoc analysis of the multicenter TROG 03.04 RADAR and PCS IV randomized...

Long term results of a phase I dose escalation trial of ablative stereotactic body radiation therapy - International Journal of Radiation Oncology, Biology, Physics redjournal.org Abstract Stereotactic body radiation therapy (SBRT) is increasingly used for oligometastatic disease as well as palliation, but treatment protocols for non-spine bone and nodal metastases are lacking, with a wide variety of schedules applied. Therefore, a prospective dose-escalation trial was initiated, involving 90 patients, among whom 52 (58%) had primary prostate tumors, 13 had breast tumors (14%), and 25 (28%) had other primary tumor types.  All visible lymph node and/or non-spine bone oligometastases were treated in three consecutive cohorts: 5×7.0 Gy, 3×10.0 Gy, or 1×20.0 Gy. Initial results revealed no dose-limiting toxicity after a median follow-up of 17.2 months. This ...

Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials - International Journal of Radiation Oncology, Biology, Physics redjournal.org Abstract Purpose A suboptimal prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) among men who go on to receive definitive radiotherapy for prostate cancer might suggest the existence of castration-resistant disease or altered androgen receptor (AR) signaling. This in turn may portend worse long-term clinical outcomes, especially in men with high-risk disease. We set out to evaluate the prognostic impact of poor PSA response to neoadjuvant ADT in men with high-risk prostate cancer. Methods and Materials This was a post hoc analysis of the m...

Association of prostate cancer with human papillomavirus infections: a case-control study | Prostate Cancer and Prostatic Diseases nature Published: 14 December 2023 Shuo-Han Yin ,  Shiu-Dong Chung , Shih-Han Hung , Tsai-Ching Liu &  Herng-Ching Lin   Prostate Cancer and Prostatic Diseases ( 2023 ) Cite this article Metrics details Abstract Background The highly oncogenic human papillomavirus (HPV) is associated with numerous cancer types. While the role of viruses in the development of certa...

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases nature Review Article Published: 14 December 2023 Fabio Turco , Silke Gillessen , Giorgio Treglia , Karim Fizazi , Matthew R. Smith , Bertrand Tombal , Richard Cathomas , Consuelo Buttigliero , Massimo Di Maio , Marcello Tucci & Ursula M. Vogl   Prostate Cancer and Prostatic Diseases ( 2023 ) Cite this article Metrics details Abstract Background Darolutamide is an androgen receptor pathway inhibitor (ARPI) used in p...

A genome wide CRISPR screen reveals that HOXA9 promotes Enzalutamide resistance in prostate cancer | bioRxiv biorxiv.org Michael V. Roes, View ORCID ProfileFrederick A. Dick 0 1 0 0 2 0 TRiP Peer Reviews 0 Community Reviews 1 Automated Services 0 Blog/Media Links 0 Videos 2 Tweets Abstract Androgen receptor inhibitors are commonly used for prostate cancer treatment, but acquired resistance is a significant problem. Co-deletion of RB and p53 is common in castration resistant prostate cancers, however they are difficult to target pharmacologically.  To comprehensively identify gene loss events that contribute to enzalutamide response, we performed a genome-wide CRISPR knockout screen in LNCaP prostate cancer cells. This revealed novel genes implicated in resistance that are largely unstudied. Gene loss events that confer enzalutamide sensitivity are en...